Cours suspendu

Communiqués Decoy Therapeutics Inc. Börse Stuttgart

Actions

FP11

US79400X6022

Recherche biotechnologique et médicale

Marché Fermé - Börse Stuttgart 17:48:59 14/06/2024			Varia. 5j.	Varia. 1 janv.
3,104 ^EUR	-3,96%		+704,15%	+435,17%

12/08	Decoy Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
27/07	Decoy Therapeutics démontre l'activité in vitro de son candidat D-MAV contre le virus Ebola Zaïre de type sauvage et lance un programme exploratoire contre les filovirus, dont Ebola et Marburg	CI

Communiqués

12/08	Decoy Therapeutics: Q2 Earnings Snapshot	AQ
27/06	Decoy Therapeutics : Announces Up to $21 Milli...	PU
26/05	Decoy Therapeutics : Names Brad Pentelute, MIT Profe...	PU
26/05	Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board	PR
08/05	Decoy Therapeutics: Q1 Earnings Snapshot	AQ
27/04	Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston	PR
06/04	Decoy Therapeutics : to Participate in Virtual Inves...	PU
06/04	Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026	PR
02/04	Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	PR
11/03	Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform	PR
05/03	Decoy Therapeutics : Announces 1-for-12 Reverse Stoc...	PU
05/03	Decoy Therapeutics Announces 1-for-12 Reverse Stock Split	PR
11/02	Decoy Therapeutics Joins Webull Corporate Connect Service Platform	PR
05/02	Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial	PR
04/02	Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement	PR
13/01	Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform	PR
07/01	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics	AQ
19/12	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting	AQ
18/12	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform	AQ
01/12	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study	AQ
20/11	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX	AQ
19/11	Salarius Pharmaceuticals : Cites Errors on S&P CapIQ...	PU
19/11	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”	AQ
14/11	Salarius: Q3 Earnings Snapshot	AQ
13/11	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger	AQ